Receipt date: 07/13/2006

10579695 - GAÇJ; 8751

Attorney's Docket No. 048109/308904

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Sarma et al.

Confirmation No.: To Be Assigned

10/579,695

Art Unit:

To Be Assigned

March 3, 2006 Examiner: To Be Assigned

A PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF INVASIVE PULMONARY ASPERGILLOSIS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449 listing several documents that were first cited in the International Search Report for the corresponding International Application Number PCT/IN05/00429 not more than three months prior to the filing of this Statement. In this regard, Applicant notes that the International Search Report was not received by any individual designated by 37 CFR 1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By identifying the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead identifying the listed documents for the sake of full disclosure.

Respectfully submitted,

Edward R. Ergenzinger

Registration No. 47,549 **CERTIFICATE OF MAILING** 

I hereby certify that this correspondence is being deposited with the

an envelope addressed to: Commissioner for Patents, P.O. Box 1450,

United States Postal Service with sufficient postage as first class mail in

CUSTOMER NO. 00826 ALSTON & BIRD LLP

Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200

Fax Raleigh Office (919) 862-2260

Pamela Lockley

LEGAL02/30008803v1

Alexandria, VA 22318-1450, on July 11, 2006.

Receipt date: 07/13/2006 PE

Sheet

	<del></del>
Substitute for form 14 (Revised 07/2005)	1 6 1
,	(بىر 7006 ئى JUL 1 ئى
INFORMAT	ON DISCLOSTRE
STATEMEN	T BALAPPIA CANT
(Use as man	ny sheets as necessary)

of

Complete if Known				
Application Number	10/579,695			
Filing Date	March 3, 2006			
First Named Inventor	Sarma			
Group Art Unit	To Be Assigned			
Examiner Name	To Be Assigned			
Attorney Docket Number	048109/308904			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document  Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached	
	1	WO 00/69894	11-23-2000	Thiel et al.			
	2	WO 03/033522 A1	04-24-2003	Natimmune A/S			
	3	WO 03/090774 A1	11-06-2003	The Council of the Queensland Institute of Medical Research			
	4	WO 2004/089394 A2	10-21-2004	Natimmune A/S			
	5	WO 2006/067807 A1	06-29-2006	Council of Scientific and Industrial Research			

		OTHER DOCUMENTS	
Examiner Initials*	Cite No.		
	6	CROSDALE, D. J, et al., "Mannose-Binding Lectin Gene Polymorphisms as a Susceptibility Factor for Chronic Necrotizing Pulmonary Aspergillosis," <i>JID</i> , 2001, pp. 653-656, Vol. 184.	
	7	NETH, O., et al., "Interaction of Human Mannose-Binding Lectin (MBL) to Organisms Isolated from Immunocompromised Children," p. 362, (Abstract).	
	8	NETH, O., et al., "Mannose-Binding Lectin Binds to a Range of Clinically Relevant Microorganisms and Promotes Complement Deposition," <i>Infection and Immunity</i> , 2000, pp. 688-693, Vol. 68 (2).	
	9	VALDIMARSSON, H., et al., "Reconstitution of Opsonizing Activity by Infusion of Mannan-Binding Lectin (MBL) to MBL-Deficient Humans," Scand. J. Immunol., 1998, pp. 116-123, Vol. 48.	

LEGAL02/30003711v1

Examiner	(magnet) at 2 2 2 1	Date	00/05/0010
Signature	/Timothy L. Maust/	Considered	03/23/2010

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.